“antibodies” Archives

in
Entry Author Date Location
Racing Zika: For Every Short Cut, There’s An Open Question 03/15/16 National
Ensemble Quietly Amasses Cancer Drug Pipeline, Scouts for New Deals 03/08/16 Boston
InCube Labs Startup Fe3 Plans Iron-Delivering Patch For Anemia 03/04/16 Texas
Adicet Joins the Immunotherapy Fray With $51M and Mystery Cells 01/27/16 San Francisco
No Drug Yet In Clinic, But CytomX Raises $80M In Discounted IPO 10/08/15 San Francisco
Avitide Gets $7.6M More to Purify Complex Biologics 08/06/15 Boston
Sanofi, Regeneron Set Sights on Immuno-Oncology With New $2B+ Pact 07/28/15 New York
Bluebird Adds to CAR-T Arsenal With Five Prime Antibody Deal 05/26/15 Boston
Moderna Forms Latest Venture, Valera, to Fight Infections With mRNA 01/08/15 Boston
Diagnosis On-demand: Methodist Develops V-chip Medtech Device 04/11/14 Texas
Tillman Gerngross, the Scientist Turned Scientific Businessman 01/09/14 Boston
Seattle Genetics Nabs $25M More From AbbVie for Souped Up Antibodies 01/08/14 Seattle
PharmAthene Backs Out of Theraclone Sciences Merger 12/02/13 Seattle
iPierian Nabs $30M To Keep Alzheimer’s, Autoimmune Drugs Moving 09/04/13 San Francisco
Adimab Teams Up With Celgene, Innovent, in Latest Partnership Deals 08/20/13 Boston
Celgene Emerges as Biotech’s Shrewdest, Nimblest Dealmaker 08/05/13 National
Theraclone Merges With PharmAthene, Plans to Stay in Seattle 08/01/13 Seattle
Adimab Turns Cash Flow Positive With GSK, Biogen Tech Transfer Deals 07/26/13 Boston
Applying “Innovation Arbitrage” to Develop Novel Medicines in China 05/28/13 San Diego
Memorial Sloan-Kettering and Eureka Go After ‘Undruggable’ Targets 03/21/13 New York
Allozyne Conducts Round of Employee ‘Furloughs’ 03/15/13 Seattle
Some Bold Baseball and Biotech Picks for the 2013 Season 03/11/13 National
Genentech, ImmunoGen Win FDA OK for Souped-Up Breast Cancer Drug 02/22/13 San Francisco
Adimab Grows Up, Looks to Pay Off the VCs In Unusual Way 02/22/13 Boston
The Holy Grail of Drug Development: Small Molecules with the Power of Biologics 02/14/13 Boston
Third Rock’s Latest, Jounce, Grabs $47M For Cancer Immunotherapy 02/14/13 Boston
Alnylam Gets $25M From Medicines Co. for Cholesterol Drug 02/04/13 Boston
Alder Biopharma Looks to Take On Migraines, and the World 01/24/13 Seattle
Sutro Strikes Celgene Deal Worth Up to $500M 12/18/12 San Francisco
Seattle Genetics Gets $25M in Broader Abbott Deal 10/23/12 Seattle
Page 1 of 5 next page »